Behind-The-Counter Sale Is No Deterrent To Brand Loyalty – Survey
This article was originally published in The Tan Sheet
Behind-the-counter status does not diminish customers' loyalty to brand name nonprescription drugs, according to results of a nationwide survey
You may also be interested in...
The growth of in-store health care clinics could lead to consumers more often opting for OTC products over receiving prescriptions, but also creates the possibility for the appearance of conflicts of interest involving the host retail sites and the clinic operators, health care association executives say
FDA's interest in establishing an official third class of drugs, as well as the OTC industry's concern about the idea, could be diminished because the agency already allows a path to behind-the-counter sales in new drug and switch applications, according to a former FDA chief counsel
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.